Cancer
Serial Killer
Patented TriKE® Technology creates cancer cell serial killers
The Future of Cancer Treatment
Natural Killer cells are one of the immune systems most effective ways to fight off cancer. However, current treatment options are limited, costly, and come with serious side effects.
GTBP's proprietary TriKE® technology causes NK cells to become cancer serial killers. Our FDA clinical trial results demonstrate the TriKE's ability to engage your body's own NK cells to target and kill cancer cells. (*See video of NK cells in action at right).
Join us for an exclusive presentation to learn more about the science and benefits of our proprietary TriKE® therapies for the treatment of cancer.
NK cell killing cancer cells
- Cancer Cells
- 1 Natural Killer Cell
- Dead Cancer Cells
Currently in FDA clinical trials
Cancer
Clinical
benefit achieved
Demonstrated clinical benefit from reduced cancer levels seen in phase 1
UP TO 63%
reduction
In cancer levels in phase I clinical trials
NO HARMFUL
SIDE EFFECTS
Like cytokine storm
Not A CELL
THERAPY
Higher doses show a clean safety profile
NK CELL
Durability
Increases NK cell numbers without cell therapy
Why our TriKE® Technology is changing cancer therapy in 1 minute
Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.
elite management team
We have the science and strategy to succeed
CEO
Anthony Cataldo
Started Iovance, a $7B biotech company
Mr. Cataldo founded GT Biopharma Inc. upon joining the Board of Directors and subsequently Chairman and CEO in in July of 2014, where he changed the Company's profile with the inclusion of oncology assets. From February 2011 to June 2013 Mr. Cataldo served as Founder and Chairman/CEO of Iovance Biotherapeutics, Inc., (IOVA).
Mr. Cataldo created the highly successful IOVA/Genesis with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma.
Consulting Chief Medical Officer and Chief Scientific Officer
Dr. Jeffery Miller
Leading expert on NK cells
Jeffrey S. Miller, MD, is currently a Professor of Medicine at the University of Minnesota. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. He has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 170 peer-reviewed publications.
He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for Blood and is a reviewer for a number of journals and NIH grants.
Our clinical trial results
Patient 9 achieved a 63% reduction in bone marrow blast levels
Using the latest NK Cell technology, our science exceeds our value based on the competition
All of us are trying to have an NK cell kill a cancer cell, however only our proprietary TriKE® technology creates new NK cell "serial killers" in your body.
 |
 |
 |
 |
|
|---|---|---|---|---|
| Market cap | $8.64B | $1.35B | $1.1B | $300M and growing |
| NOT A CELL THERAPY |  |
 |
|
|
| No Side Effects | |
|
|
|
| INCREASES PATIENTS ENDOGENOUS NK CELL NUMBERS | |
|
|
|
| Cost effective treatment | |
|
|
|
Scroll to View Table
Solving the economic issue of cancer treatment
Cost
Cell therapy is one of the most expensive treatment options costing $500,000 to $2,000,000 per patient.
Our per patient cost is up to $300,000 and is covered by insurance.
cell therapy
UP TO
$2,000,000
per patient
Trike® expected cost
UP TO
$300,000
per patient
Coverage
Cell Therapy is also limited to helping 4-5,000 patients per year when millions of people need this treatment. By using a protein biologic drug hundreds of thousands of patients will receive treatment.
Cell Therapy is limited due to high manufacturing costs, limited supply and lack of clinical utility. It only works in very few use cases. TriKE therapy has none of these limitations.
Previously
limited to small patient populations
Upcoming
HUNDREDS Thousands of patients
WATCH NOW!
Learn more about our revolutionary technology TriKE® and how GTBP support will create measurable results for the future of cancer treatment.
Forward-Looking Statements
This video presentation contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes”, “hopes”, “intends”, “estimates”, “expects”, “projects”, “plans”, “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking.
Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Form 10-K for the fiscal year ended December 31, 2020 in the section titled “Risk Factors” in Part I, Item 1A and in our subsequent Form 10Q Quarterly filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.
Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to
to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control.
Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.
We intend that all forward-looking statements made in this video presentation will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this video presentation.
Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements. Stock data may be delayed by at least 15 minutes. Data is provided for information only and should not be used as the basis for share trading. GT Biopharma, Inc. accepts no liability for errors and/or delays in data or for transactions carried out on the basis thereof.